Archive

Over 100 delegates participate in the conference

In the run up to our 18th Anniversary issue, we ran a poll on our website, with the motion of the house being: The Indian patent…

Synribo blocks certain proteins that promote the development of cancerous cells

Net profit for Q2 was Rs 1567.52million as compared to Rs 782.75 million for the previous quarter

Revenues from the global generics segment primarily driven by North America, India and other emerging markets

Will offer the seamless contract development and manufacture of antibody drug conjugates

The patent is valid till February 2026

Year-to-date sales and net income goes down

Receives US FDA approval

Award to be given in individual and organisation category